Market cap
$128 Mln
Revenue (TTM)
$168 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 30.31 | 38.13 | 66.00 | 78.07 | 100.83 |
| EBIT | 41.70 | 30.02 | 34.76 | 14.79 | 8.83 |
| Net Profit | 27.75 | 34.06 | 29.07 | 11.69 | 6.22 |
| EPS | 28.23 | 38.96 | 35.79 | 16.99 | 10.50 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -79.39 | -303.98 | -26.44 | -30.65 | -34.01 |
| Net Margin
| -120.97 | -311.13 | -39.82 | -41.93 | -48.83 |
| Return on equity
| 85.89 | -628.11 | -- | 42.54 | 51.37 |
| Return on Capital
| -54.65 | -52.51 | -- | -59.04 | -42.55 |
| Return on Assets
| -40.92 | -43.59 | -24.76 | -35.67 | -32.76 |
| Debt to Equity (x)
| -- | -- | -0.47 | -1.51 | -2.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
--
|
-59.04
|
-42.55
|
-62.36
|
-51.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
--
|
42.54
|
51.37
|
163.76
|
-3,225.80
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
-24.76
Lower than Peers by 27.62
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
-24.76
|
-35.67
|
-32.76
|
-54.34
|
-46.72
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
-26.44
Lower than Peers by 42.26
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
-26.44
|
-30.65
|
-34.01
|
-173.50
|
-698.92
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
-39.82
Lower than Peers by 48.05
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
-39.82
|
-41.93
|
-48.83
|
-272.14
|
-640.17
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
66.00
Higher than Peers by 57.95
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
66.00
|
0.25
|
1.78
|
1.63
|
-0.03
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
34.76
Higher than Peers by 26.50
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
34.76
|
-12.35
|
45.53
|
34.70
|
-15.90
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
29.07
Higher than Peers by 21.34
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
29.07
|
-7.59
|
49.18
|
9.73
|
-14.63
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
35.79
Higher than Peers by 25.40
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
35.79
|
0.03
|
0.53
|
0.34
|
-0.09
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
-24.79
Lower than Peers by 29.66
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
-24.79
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.47
Lower than Peers by 1.06
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
-0.47
|
-1.51
|
-2.00
|
-2.46
|
-6.62
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.81
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
-0.81
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.52
Lower than Peers by 1.13
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
0.52
|
3.66
|
4.86
|
6.85
|
10.06
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
0.46
Lower than Peers by 0.74
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
0.46
|
3.22
|
4.51
|
6.24
|
9.58
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
-2.32
Lower than Peers by 7.09
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
-2.32
|
-2.55
|
-2.36
|
-3.73
|
-7.05
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
25.34
Higher than Peers by 4.07
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
25.34
|
51.75
|
27.38
|
36.15
|
57.92
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.62
Higher than Peers by 0.22
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
0.62
|
0.85
|
0.67
|
0.20
|
0.06
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
--
|
134.62
|
73.76
|
106.24
|
108.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
--
|
218.50
|
216.89
|
551.70
|
-1,606.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
--
|
84.77
|
61.12
|
125.16
|
325.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
--
|
268.35
|
229.53
|
532.78
|
-1,822.97
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
--
|
-1.60
|
-3.74
|
-2.47
|
-1.06
|
|
Peer Median
|
37.32
|
--
|
--
|
--
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
--
|
-0.59
|
-1.73
|
-2.81
|
-3.43
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
-4.43
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
-4.43
|
-7.26
|
-9.37
|
-5.60
|
-1.64
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
128
Lower than Peers by 2,393
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Paratek Pharmaceuticals (PRTK)
|
128
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,521
|
--
|
--
|
--
|
--
|